Navigation Links
NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
Date:10/25/2007

Anti-Tumor Activity of NKTR-102 Associated With Increased and Sustained

Exposure of Tumor Tissue to the Active Metabolite of Irinotecan

SAN FRANCISCO, Oct. 25 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented positive preclinical data today on its proprietary product candidate NKTR-102 (PEG-irinotecan) at the AACR-NCI-EORTC International Conference in San Francisco, California. The presentations highlighted the anti-tumor activity and unique pharmacokinetic profile of NKTR-102 in preclinical models of colorectal, lung and breast cancer. NKTR-102 is a PEGylated form of irinotecan developed using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.

In the two data presentations today, NKTR-102 inhibited tumor growth by greater than 90% in mouse xenograft models of colorectal (HT29), lung (NCI- H460) and breast (MCF-7) cancers as compared to controls. The studies also demonstrate that Nektar's small molecule PEGylation technology improves the pharmacokinetics of irinotecan by increasing the effective half-life of irinotecan's active metabolite in tumor tissues. In a colorectal cancer model, the half-life was increased to 15 days following NKTR-102 administration versus 4 hours following irinotecan.

"The studies presented today at the 2007 AACR-NCI-EORTC Conference highlight the superior tumor suppression properties of NKTR-102 relative to irinotecan in colorectal, lung and breast cancer models," stated Hoyoung Huh, M.D., Ph.D., Chief Operating Officer and Head of the PEGylation Business Unit at Nektar. "NKTR-102 demonstrates improved half-life and tumor exposure to irinotecan's active metab
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
3. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
4. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
5. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
6. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
7. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
8. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
9. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
10. Introgens Advexin Demonstrates Clinical Benefit in Inherited Cancer
11. Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... BURLINGTON, Mass. , Aug. 20, 2014 ... Japanese electrophysiology (EP) mapping and ablation device ... increasingly use ablation to treat atrial fibrillation ... a primary treatment option for AF will ... for this application, such as advanced loop ...
(Date:8/20/2014)... 2014  Amerigen Pharmaceuticals Ltd. announces that its ... received Chinese FDA (CFDA) approval and has subsequently ... the China domestic market.  ... agreement with Sinochem Jiangsu Pharmaceutical Co., Ltd., Amerigen ... approved and China CFDA certified oral solid dose ...
Breaking Medicine Technology:Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 2Electrophysiology Mapping and Ablation Device Market in Japan to Reach $1.1 Billion by 2023 3Amerigen Pharmaceuticals Ltd. announces that its Chinese subsidiary, Suzhou Amerigen Pharmaceuticals Co. Ltd., has received Chinese FDA (CFDA) approval and has subsequently launched its generic Mecobalamin 0.5 mg Tablets into the China domestic mark 2
... Sequenom, Inc. (Nasdaq: SQNM ) today announced ... company at the following conferences in November. ... ) Lazard Capital Markets 7th Annual ... York, NY Presentation date: Tuesday November 16, 2010 ...
... Pharmaceuticals today announced it has discovered that EVP-6124, its ... not previously seen in the scientific community: it acts ... By acting as a co-agonist and sensitizing ... amounts of naturally occurring ACh, typically found in individuals ...
Cached Medicine Technology:Sequenom to Present at Two Financial Conferences in November 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 2EnVivo Pharmaceuticals Research Shows EVP-6124 Acts as Acetylcholine Co-Agonist 3
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... "I decided that there needed to be a ... without the hassles associated with using conventional oral devices," ... DR. GATES ORAL-HYGIENE TOOL provides an easy way to ... oral hygiene and fresh breath, and it eliminates the ... eco-friendly and easy to use, the device is producible ...
(Date:8/20/2014)... extracted acellular allogeneic nerve, from which Schwann ... been removed, reduced postoperative immune rejection. Simultaneously, ... substrates and base materials, such as the ... provide a good scaffold in the process ... nerve, similar to autologous nerve transplantation, can ...
(Date:8/20/2014)... 20, 2014 Doctors at the University of ... out mesothelioma in laboratory mice by injecting them with a ... details of the study on its website. Click here ... Hong Kong University’s AIDS Institute of Microbiology created a vaccine ... PD-1. By altering DNA, the vaccine is designed to prevent ...
Breaking Medicine News(10 mins):Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2
... cuts side effects , , MONDAY, May 11 (HealthDay ... mesylate (CM) to the conventional two-drug regimen of ... vomiting (CINV) in patients undergoing highly emetogenic chemotherapy ... used to treat many types of solid tumor ...
... DNA offers insights to better treatments, scientists say , , ... studies have identified what researchers describe as a treasure ... "In one fell swoop, to find so many genes ... the lead author of one of the studies, Dr. ...
... for People with Epilepsy Now Accepting EntriesTITUSVILLE, N.J., May ... for centuries, with most agreeing that art means something ... can be a self-expressive, visual demonstration of how it ... Expressions of Courage (R) is a national contest for ...
... mild , , MONDAY, May 11 (HealthDay News) -- Confirmed ... to more than 2,500 by Monday, and the U.S. now ... according to World Health Organization figures. , The number of ... the weekend, with health officials in Washington state reporting late ...
... MedCath Corporation (Nasdaq: MDTH ), ... services, predominately the diagnosis and treatment of cardiovascular ... its senior management team as Senior Vice President, ... hospitals located in Arizona, California, New Mexico as ...
... Shaver, will be an invited panelist in the second annual SOA in ... Illinois. , ... Plano, Texas (PRWEB) May 11, 2009-- Corepoint Health,s CTO, ... in Healthcare conference to be held on June 2 - 4 in ...
Cached Medicine News:Health News:3-Drug Combo Reduces Nausea After Chemo 2Health News:Genes Yield Clues to High Blood Pressure 2Health News:Genes Yield Clues to High Blood Pressure 3Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 2Health News:Every Picture Tells A Story, Particularly for Those With Epilepsy 3Health News:U.S. Now Leads World in Swine Flu Cases 2Health News:U.S. Now Leads World in Swine Flu Cases 3Health News:U.S. Now Leads World in Swine Flu Cases 4Health News:U.S. Now Leads World in Swine Flu Cases 5Health News:U.S. Now Leads World in Swine Flu Cases 6Health News:U.S. Now Leads World in Swine Flu Cases 7Health News:U.S. Now Leads World in Swine Flu Cases 8Health News:U.S. Now Leads World in Swine Flu Cases 9Health News:U.S. Now Leads World in Swine Flu Cases 10Health News:U.S. Now Leads World in Swine Flu Cases 11Health News:David Covert to Join MedCath as Senior Vice President, Operations 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 2Health News:Corepoint Health CTO to Participate in Panel Discussion at the 2009 SOA in Healthcare Conference 3
Stylish yet conservative, these classics are reliable, comfortable and durable....
Safilo Design, a state-of-the art ophthalmic collection that blends technology with minimalist sophistication. Each style comes with a sleek silver-colored hard case with magnetic closure....
Inquire...
Classic, stylish, and preppy, this collection features men's, women's and unisex styles....
Medicine Products: